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Available online 10 October 2013Abstract Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft
failure and severe graft-versus-host disease (GVHD). Mesenchymal stromal cells (MSCs) have been shown to support in vivo
normal hematopoiesis and to display potent immunesuppressive effects. We cotransplanted the culture-expanded third-party
donor-derived umbilical cord MSCs (UC-MSCs) in 21 young people with severe aplastic anemia (SAA) undergoing haplo-HSCT
without T-cell-depleted. We observed that all patients had sustained hematopoietic engraftment without any adverse UC-MSC
infusion-related events. Furthermore, we did not observe any increase in severe aGVHD. These data suggest that UC-MSCs,
possibly thanks to their potent immunosuppressive effect on allo-reactive host T lymphocytes escaping the preparative
regimen, reduce the risk of graft failure and severe GVHD in haplo-HSCT.
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Open access unIntroductionAllogeneic hematopoietic stem cell transplantation (HSCT) is
an effective therapeutic modality for young patients with
severe aplastic anemia (SAA) who have an immediate HLA-
identical donor. However, less than 30% of patients who
require allogeneic HSCT have a human leukocyte antigen
(HLA)-compatible sibling. In China, searching for HLA-matched
donors is usually unsuccessful because no siblings are available
for almost all young people. Fortunately, haplo-identicalder the CC BY-NC-ND license.
133Cotransplantation for severe aplastic anemiahematopoietic stem cell transplantation (haplo-HSCT) has
come into clinical use to treat hematologic malignancies and
the protocols have been greatly improved during the last
decade (Guo et al., 2009; Lazarus et al., 2005). However,
the results of haplo-HSCT in patients with SAA have been
disappointing, due to high risk of treatment-related mortality
(TRM) because of infection, bleeding, regimen-related toxicity,
engraftment failure, and acute and chronic graft-versus-host
disease (aGVHD, cGVHD) (Woodard et al., 2004; Lazarus and
Koc, 2001; Tsutsumi et al., 2004; Tabbara et al., 2002).
Mesenchymal stem cells (MSCs) are a heterogeneous subset
of multipotent stromal stem cells, which express low levels of
class I, but not class II, histocompatibility antigens and are not
immunogenic in in vitro assays or preclinicalmodels (Le Blanc et
al., 2008; D.P. Lu et al., 2006; L.L. Lu et al., 2006). MSCs have
also been shown to suppress primary and ongoing mixed
lymphocyte reactions (Klyushnenkova et al., 1998; Di Nicola
et al., 2002; Ball et al., 2007). MSCs can be isolated from many
adult tissues, including bone marrow (BM), periosteum, adipose
tissue, fetal liver, cord blood and umbilical cord (UC) tissues
(In't Anker et al., 2003; Lee et al., 2004; Romanov et al., 2003).
Recently, some experimental and clinical data demonstrated
that BM-MSCs can support hematopoiesis, enhance the
engraftment of HSCs, and reduce the incidence of GVHD
following HSCT (Guo et al., 2009; Lazarus et al., 2005).
However, the aspiration of BM involves invasive procedures,
and the frequency and differentiation potential of BM-MSCs
decrease significantly with age (D.P. Lu et al., 2006; L.L. Lu
et al., 2006). Lu LL et al. have shown that a large number of
MSCs can be easily isolated from the UC and collected using
an accessible and painless procedure (D.P. Lu et al., 2006;
L.L. Lu et al., 2006). Our recent data demonstrated that the
modified haplo-HSCT combined with third-party donor-derived
UC-MSCs for 50 patients with refractory/relapsed hematologic
malignancy was not only safe and feasible but also effective for
the improvement of donor engraftment and the reducing of
severe GVHD (Wu et al., 2013). However, it is still unknown
whether cotransplantation of UC-MSCs in haplo-HSCT recipients
with SAA can reduce graft failure.
Herein, we report the results of our clinical trial of haplo-
HSCT with modified conditioning that was designed primarily to
examine the safety and feasibility of the cotransplantation of
culture-expanded third-party donor-derived UC-MSCs and donor
HSCs in SAA patients. We further investigated the rates and
kinetics of hematopoietic engraftment and the incidence and
severity of GVHD.Results
Engraftment and chimerisms
In Table 1, the median hematopoietic cell doses infused were
9.28 × 108 mononuclear cells (range, 6.30–13.18 × 108/kg) and
3.79 × 106 CD34+ cells (range, 1.96–10.20 × 106/kg). Data for
all patients who survived at least 30 days after transplantation
andwere evaluable for engraftment are summarized in Table 2.
Overall, the median time to achieve neutrophil engraftment
(absolute neutrophil count ≥0.50 × 109/L) was 12.0 days
(range, 8.0–21.0 days). Overall, the median time to achieve
platelet engraftment ≥20 × 109/L was 14.0 days (range,
10.0–23.0 days). Delayed platelet recovery (N30 days) wasnot observed in any of the 21 patients. All patients achieved
full donor chimerism (FDC) (Table 2).
GVHD
Table 2 indicates the incidence and severity of GVHD. Overall,
12 of 21(57.1%) patients experienced aGVHD between 20 and
78 days after transplantation, including 3 (14.3%) with grade I,
4(19.0%) with grade II, 4 (19.0%) with grade III and 1 (4.8%)
with grade IV aGVHD. The other 9 patients had no aGVHD. Ten
of 20 (50.0%) evaluable patients who survived at least 90 days
after transplantation experienced cGVHD; cGVHD was limited
in 7 patients (35.0%) and extensive in 3 patients (15.0%).
Survival
Upon follow-up for 2.5 to 78 months, 17 of the 21 (80.9%)
patients were alive. As shown in Fig. 1, the probabilities of
2-year disease-/progression-free survival were 74.1% in
the 21 patients. No patients experienced disease relapse or
progression. Four patients died; three patients died as a result
of infection, and the other patients died as a result of GVHD.
Clinical safety outcomes
As anticipated for the HSC transplant recipients, all 21
patients experienced at least 1 adverse event during the
study period, and 16 of 21 (76.2%) patients developed at
least one grade IV adverse event (Table 3). Only 4 patients
(19.0%) demonstrated adverse events that were considered
treatment related, such as GVHD, organ failure, or others
(i.e., possibly, probably, or definitely). However, no patients
experienced infusional toxicity during the UC-MSC infusion.
Discussion
Graft failure and rejection for patients with acquired
SAA remains as one of the important and life-threatening
complications, especially in haplo-HSCT (Wagner et al., 1996;
Passweg et al., 2006). The EBMT showed that for patients
receiving HLA-identical sibling grafts, the rate of graft failure
was more than 10% before 2000 (Bacigalupo et al., 2000). Over
several decades, various transplant strategies have been
introduced to decrease graft failure, with mixed success
(Wang et al., 2009; Fang et al., 2008, 2009; Wagner et al.,
1996; Passweg et al., 2006; Storb et al., 1986; DE Medeiros
et al., 2001). In this study, all patients with SAA received 1 of 2
study-specified modified conditioning regimens without T-cell
depletion for HLA-haplo relative HSCT. All patients with 2–3
mismatched loci achieved sustained full donor engraftment
and prompt hematopoietic recovery. Results suggested
that the modified conditioning regimen without high-dose
immunosuppressive agents was sufficient to achieve sustained
donor engraftment in which the third-party donor-derived
UC-MSCs may play an important role.
In allogeneic stem cell transplantation, MSC may be used
for GVHD prophylaxis and treatment of severe aGVHD (Wang
et al., 2009; Fang et al., 2008, 2009; Le Blanc et al., 2004;
Lazarus and Koc, 2001). Le Blanc demonstrated that the
infusion of MSCs was an effective therapy for patients with
Table 1 Demographic and transplant characteristics of patients and donors.
Case Sex/Age Status prior to
Co-transplantation
Donor/Age HLA mismatch ABO pairs
D/R
MNC 108/kg Cd34+ 106/kg
1 M/29 VSAA ⁎ Brother/22 A B DR A/A 6.65 2.45
2 M/18 VSAA a,g,⁎ Father/44 B DR A/A 8.80 6.60
3 M/19 VSAA c,f,⁎ Sister/23 A B B/O 9.28 5.88
4 F/23 VSAA d,f,⁎ Sister/18 A DR O/A 9.66 6.94
5 F/12 VSAA e,⁎ Sister/16 A B DR A/B 8.85 3.92
6 M/13 VSAA b,g,⁎ Father/40 A B DR O/O 7.74 7.52
7 M/16 SAA & PNH g,# Mother/42 A B O/O 10.20 4.84
8 M/4 VSAA ⁎ Mother/30 A B DR AB/B 10.20 3.10
9 M/24 VSAA c,⁎ Mother/48 A B DR A/AB 8.06 3.45
10 F/23 SAA a,b,g,⁎ Mother/48 A B DR B/AB 8.44 1.96
11 F/12 SAA g,⁎ Mother/35 A B DR O/O 9.96 10.20
12 F/15 SAA f,⁎ Sister/27 B DR B/B 6.30 3.75
13 F/25 VSAA ⁎ Mother/48 A B DR A/A 9.85 3.20
14 F/15 VSAA ⁎ Father/44 A B DR B/B 13.18 7.96
15 M/16 SAA g,⁎ Father/43 A B DR AB/A 8.82 3.25
16 F/19 VSAA ⁎ Brother/21 A DR B/O 10.56 4.55
17 M/21 SAA g,⁎ Father/41 B DR O/A 10.06 3.79
18 M/13 VSAA ⁎ Mother/34 A B DR A/A 10.97 3.47
19 M/23 SAA b,g,⁎ Mother/51 A B B/B 7.90 2.97
20 F/31 SAA & PNH g,# Mother/57 A B DR O/O 8.58 3.11
21 F/9 SAA f,⁎ Mother/32 B DR A/A 9.62 4.71
MNC, mononuclear cells; F, female; M, male; HLA, human leukocyte antigen; SAA, severe aplastic anemia; VSAA, very severe aplastic
anemia; PNH, paroxysmal nocturnal hemoglobinuria; ATG, rabbit anti-human T-lymphocyte immunoglobulin; D, donor; R, recipient.
a First graft failure.
b Relapse after ATG.
c Viral hepatitis before aplastic anemia.
d Thyroid carcinoma before aplastic anemia.
e Viral encephalitis before aplastic anemia.
f More than 15 units red blood cells were transfused.
g More than 25 units red blood cells were transfused.
⁎ Conditioning regimen 1.
# Conditioning regimen 2.
134 Y. Wu et al.steroid-resistant GVHD in a phase II clinical trial (Le Blanc
et al., 2008). Lu et al. showed that UC-MSCs do not express
the immune costimulatory molecules or HLA-DR and express
low levels of HLA-ABC (D.P. Lu et al., 2006; L.L. Lu et al., 2006).
In our center, the results of haplo-HSCT were very disappointed
from January 2006 to December 2007. Five patients aged 14
to 25 with 1–2 mismatched loci received haplo-HSCT with
the same conditioning regimen and GVHD prophylaxis except
UC-MSCs. Even though no patient had graft failure, one patient
had mixed chimerisms (MC). The incidences for grades II to IV
and III/IV aGVHD were up to 60.0% and 40%, respectively. At
the same time, extensive cGVHD occurred in 1 patient (33.3%)
of 3 evaluable patients who survived at least 90 days after
transplantation. The most disappointing results were that only
2 (40.0%) patients were alive in the following 24 months. In
the present trial, we intended for GVHD prophylaxis to consist
of cyclosporine (CsA), mycophenolate mofetil (MMF), rabbit
anti-human T-lymphocyte immunoglobulin (ATG), anti-CD25
antibody (CD25Ab) and UC-MSCs, and we did not observe an
increase in severe aGVHD. Many studies have shown that the
incidences for grades II to IV and III/IV aGVHD range from 44% to
64% and from 12% to 26%, respectively. Extensive cGVHD rates
range from 30% to 46% (Bensinger et al., 2001; Couban et al.,
2002). Grade III/IV aGVHD rates (23.8%) and cGVHD (47.6%)
rates identified in the trial fall within these ranges and wouldbe a little better than the above mentioned. Similar results
were also observed in our recent studies in 50 patients with
refractory/relapsed hematologic malignancy of haploidentical
HSCT (Wu et al., 2013). All of these results suggest that
the infusion of third-party donor-derived UC-MSCs may play
a considerable role in the lessening of severe GVHD. A
randomized double-blind clinical trial evaluating the use of
third-party donor-derived UC-MSC infusion for the prevention
and lessening or treatment of GVHDwill be required to establish
the efficacy of this treatment regimen.
In comparison with other reports (Wang et al., 2009; Fang
et al., 2008, 2009; D.P. Lu et al., 2006; L.L. Lu et al., 2006)
in which large amounts (over 1 × 106/kg) of MSCs were usually
infused intravenously, we administered 5 × 105 cells/kg of UC-
MSCs to all of the patients, and the clinical outcomewas better,
with milder GVHD and stable engraftment. Our results indicate
that this dose of UC-MSCs retained an effective role. Further-
more, no adverse UC-MSC infusion-related events occurredwith
the administration of donor UC-MSCs into all patients.
In conclusion, our data demonstrate that the modified
haplo-HSCT combined with third-party donor-derived UC-MSCs
for patients with SAA was not only safe but also effective for
the improvement of donor engraftment and the lessening of
severeGVHD. Therefore, this treatment regimenmay provide a
feasible option for the salvage treatment of acquired SAA.
Table 2 The outcome of transplantations in 21 patients.
Case ANCN
0.5 × 109/L (D)
PLTN
20 × 109/L (D)
aGVHD
grade
cGVHD Chimerism
M1
Outcome (M)
1 16 17 I b Lim a 100% Alive 78
2 12 14 III a,b,c No 96.6% Dead 5, infection
3 16 18 II a,b Lim a,b 100% Alive 41
4 10 11 No No 100% Alive 39
5 11 11 IV a,b,c Ext a,c 100% Dead 6, GVHD
6 14 16 I a Lim a 98.5% Dead 13, infection
7 11 11 No Ext a,c,e 97.8% Alive 32
8 11 13 III b,c Ext a,c,d 100% Alive 18
9 13 13 II c No 100% Alive 16
10 12 15 No No 95.7% Dead 3, infection
11 12 12 No Lim a,b 99.5% Alive 20
12 21 23 No No 100% Alive 13
13 13 15 III b,c No 100% Alive 11
14 13 15 No No 100% Alive 10
15 10 14 II c No 100% Alive 7
16 10 14 No Lim b 100% Alive 6
17 8 14 III c No 100% Alive 4
18 9 10 II b,c No 100% Alive 4
19 10 14 No No 100% Alive 3
20 12 14 I a No 100% Alive 7
21 10 12 No No 100% Alive 3
ANC, absolute neutrophil count; PLT, platelets; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Ext,
extensive; Lim, limited; D, day; M, months.
M1:the first month after transplantation.
a Organ was affected by GVHD: liver.
b Organ was affected by GVHD: skin.
c Organ was affected by GVHD: intestinal.
d Organ was affected by GVHD: lung.
e Organ was affected by GVHD: eye.
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Figure 1 Disease/progression-free survival (PFS) after
transplantation. The probability of 2-year PFS for all patients
was 74.1%.
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Patients and study design
Twenty-one patients with SAA aged 4 to 31 (median 18 years),
including 11males and 10 females were enrolled in this study in
our center from January 2007 to June 2013. Detailed
information about the patients and preparation of donors
were listed Supplementary materials 1 and in Table 4
(Camitta et al., 1979). The clinical protocol and consent
forms were approved by the institutional review board
for human investigation. Patients or their legal guardians
provided written informed consent for their inclusion in the
study.
HLA compatibility was determined by low-resolution DNA
techniques for HLA-A and B loci and high-resolution DNA
techniques for HLA-DRB1 (Mickelson et al., 1993; Petersdorf
et al., 1991).UC-MSC preparation
UC-MSCs were purchased from the National Engineering
Research Center of Cell Products, State Key Laboratory of
Experimental Hematology. The immunophenotype of UC-MSCs
Table 3 Summary of adverse and severe adverse events
for all patients versus UC-MSC dose.
Variable Total (N = 9)
≥1 adverse event 21
≥1 severe adverse event 16
Fatal severe adverse event 5
Highest NCI grade or severity
Grade 1 2
Grade 2 1
Grade 3 2
Grade 4 16
Relationship ⁎
Not related 17
Related 4
At each level of summation (except for the row for ≥1 adverse
event), the patients who reported more than 1 event were
counted only once.
Data are the number of patients.
⁎ Not related indicates an unrelated or unlikely relationship;
related indicates a possible, probable, or definite relationship.
136 Y. Wu et al.was listed in Supplementary materials 2 (D.P. Lu et al., 2006;
L.L. Lu et al., 2006).
Conditioning regimen
The modified conditioning regimen was based on our
previous protocol for HLA-identical sibling HSCT. Conditioning
procedures included 1 of 2 regimens: (1) fludarabine (Flu)
30 mg/m2/day (days −5 to −2), cyclophosphamide (Cy)-5 -4 -3 -2 -1 0 +1 +4
Flu+CTX BMSC PBSC 
ATG MSC CD25Ab
MMF+C
-8 -7 -6 -5 -4 -3 -2 -1 0 +1 +
ATG MSC CD
BU CTX BMSC PBSC
M
A
B
Figure 2 Sketch of conditioning procedures. Conditioning include
to −2), cyclophosphamide (Cy) 600 mg/m2/day (days −5 to −2) a
(B) busulfan (Bu) 0.6 mg/Kg/6 h (days −8 to −5), Cy 1.8 g/m2/day (d
anti-human T-lymphocyte immunoglobulin; CD25Ab, anti-CD25 antib600 mg/m2/day (days −5 to −2) and ATG 5 mg/kg/day (days
−4 to −1) (Fig. 2A); or for SAA & PNH only (2) busulfan (Bu)
0.6 mg/Kg/6 h (days −8 to −5), Cy 1.8 g/m2/day (days −4,
−3), and ATG 5 mg/kg/day (days −4 to −1) (Fig. 2B) (Wang
et al., 2009; Fang et al., 2008, 2009).
Allogeneic HSC infusion
At the start of the study, BM and peripheral blood stem cells
(PBSCs) (the percentages of BM and PBSCs were same) were
both elected as the source of cellular rescue. Supplementary
materials 3 presented the collectionmethod of donor allogeneic
HSCs. BM and thawed PBSCs were infused intravenously through
a central venous catheter on day 0 and day 1 respectively.
UC-MSC infusion
The planned UC-MSC dosing scheme was 5.0 × 105/kg in all
patients. Before a planned UC-MSC infusion, the cells were
shipped in liquid nitrogen containers to our transplantation
center. BM infusions were performed 4 h after the completion
of UC-MSC infusion.
Prophylaxis and treatment of GVHD
GVHD prophylaxis consisted of intravenous CsA 3 mg/kg/day
in divided doses beginning the day before transplantation
(day −5) and was continued thereafter. The oral MMF dose
was 20 mg/kg/day from day −1 and was tapered off after
100 days if no aGVHD was observed. Rabbit ATG (Fresenius
AG, Oberursel, Germany) was administered intravenously at+30 +100
SA
4 +30 +100
25Ab
MF+CSA
d 1 of 2 regimens: (A) fludarabine (Flu) 30 mg/m2/day (days −5
nd ATG 5 mg/kg/day (days −4 to −1); or for SAA & PNH only
ays −4, −3), and ATG 5 mg/kg/day (days −4 to −1). ATG, rabbit
ody; MMF, mycophenolate mofetil; CsA, cyclosprin A.
Table 4 Patient demographic summary.
Characteristic Data
Age (Y)
Median 18
Range 4–31
Age at transplant (Y)
≤10 2(9.5%)
11–20 11(52.4%)
21–30 7(33.3%)
N30 1(4.8%)
Disease and status at transplantation
SAA 7(33.3%)
VSAA 12(57.2%)
SAA & PNH 2(9.5%)
Time from diagnosis to transplantation (M)
Median 6
Range 1–128
≤6 11(52.4%)
13–36 5(23.8%)
≥37 5(23.8%)
Sex
Male 11 (52.4%)
Female 10(47.6%)
Patient/Donor pairs
3 HLA loci 12(57.2%)
2 HLA loci 9 (42.8%)
ABO pairs
Pairs 12(57.2%)
Un-pairs 9 (42.8%)
Donor–recipient sex match
Match 13(61.9%)
Un-match 8(38.1%)
Donor–recipient relationship
Mother–child 10(47.6%)
Father–child 5(23.8%)
Siblings 6(28.6%)
CMV-positive donor 5(23.8%)
CMV-positive patient 12(57.2%)
SAA, severe aplastic anemia; VSAA, very severe aplastic anemia;
PNH, paroxysmal nocturnal hemoglobinuria; Y, year; M, months.
137Cotransplantation for severe aplastic anemiaa dose of 5 mg/kg/day only on days −4 to −1 before HSCT, and
CD25Ab (Basiliximab, Novartis Pharma Stein AG, Switzerland)
was administered intravenously at a dose of 0.5 mg/kg/day
only on day 4 after HSCT. Patients were advanced to oral
cyclosporine as tolerated. In the absence of GVHD, the oral
cyclosporine dose was reduced weekly by approximately 5%
beginning on or near 6 months, and therapy was usually
discontinued by one year after transplantation. Acute and
chronic GVHDwere treated according to institutional practices.
Engraftment, toxicity grading, GVHD grading and
disease assessment
All calculations were assessed from the day of HSC and UC-MSC
infusions (designated as day 0). Neutrophil and platelet
engraftment and hematopoietic chimerism evaluation have
been described in supplementary materials 4. Toxic effects
were graded using the National Cancer Institute CommonToxicity Criteria for Adverse Events (CTCAE version 4.0). Acute
and chronic GVHD was defined and graded as Supplementary
materials 5 (Storb et al., 1986; Atkinson et al., 1989). Relapse
was defined as the recurrence of disease. Death in the absence
of persistent relapse was categorized as nonrelapse mortality.
Supportive care
All of supportive cares were listed in the Supplementary
materials 6.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.10.001.
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